{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:00:04Z","timestamp":1774062004580,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1124\/dmd.120.090852","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T14:29:37Z","timestamp":1596292177000},"page":"917-924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach"],"prefix":"10.1016","volume":"48","author":[{"given":"H. Markus","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-Ichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veit J.","family":"Erpenbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janardhana","family":"Vemula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Elbast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zollinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.090852_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1124\/dmd.120.090852_bib2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2125.2012.04391.x","article-title":"Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin","volume":"75","author":"Boulton","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090852_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/jcph.127","article-title":"Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors","volume":"53","author":"Denton","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090852_bib4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.trsl.2013.08.003","article-title":"Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4","volume":"162","author":"El-Sheikh","year":"2013","journal-title":"Transl Res"},{"key":"10.1124\/dmd.120.090852_bib5","first-page":"PA4693","article-title":"Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses","volume":"50","author":"Erpenbeck","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1124\/dmd.120.090852_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/dmd.120.090852_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/cpdd.244","article-title":"Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers","volume":"5","author":"Erpenbeck","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.120.090852_bib8","unstructured":"European Medicines Agency (1987) Pharmacokinetic studies in man. https:\/\/www.ema.europa.eu\/en\/pharmacokinetic-studies-man"},{"key":"10.1124\/dmd.120.090852_bib9","unstructured":"FDA Center for Drug Evaluation and Research (2012) Clinical pharmacology and biopharmaceutics Review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202834Orig1s000ClinPharmR.pdf"},{"key":"10.1124\/dmd.120.090852_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1124\/dmd.120.090852_bib11","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1021\/ac300442v","article-title":"Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry\/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies","volume":"84","author":"Gu","year":"2012","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.120.090852_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40262-013-0097-y","article-title":"A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine","volume":"53","author":"Jamei","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.120.090852_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002512-199915030-00003","article-title":"Cyclosporin pharmacokinetics in the elderly","volume":"15","author":"Kovarik","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1124\/dmd.120.090852_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/17425255.2.3.419","article-title":"The use of isotopes in the determination of absolute bioavailability of drugs in humans","volume":"2","author":"Lappin","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.120.090852_bib15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/dmd.117.075358","article-title":"Absorption, distribution, metabolism, and excretion of the oral prostaglandin D2 receptor 2 antagonist fevipiprant (QAW039) in healthy volunteers and in vitro","volume":"45","author":"Pearson","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090852_bib16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10928-009-9139-3","article-title":"Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data","volume":"36","author":"Poirier","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.120.090852_bib17","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1002\/cbdv.200900116","article-title":"Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data","volume":"6","author":"Poirier","year":"2009","journal-title":"Chem Biodivers"},{"key":"10.1124\/dmd.120.090852_bib18","doi-asserted-by":"crossref","first-page":"101809","DOI":"10.1016\/j.pupt.2019.101809","article-title":"Fevipiprant has a low risk of influencing co-medication pharmacokinetics: impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes","volume":"57","author":"Poller","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/dmd.120.090852_bib19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0091270005280051","article-title":"The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers","volume":"45","author":"Sarapa","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090852_bib20","doi-asserted-by":"crossref","first-page":"eaao6451","DOI":"10.1126\/scitranslmed.aao6451","article-title":"DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment","volume":"11","author":"Saunders","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1124\/dmd.120.090852_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40262-013-0051-z","article-title":"A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans","volume":"52","author":"Schwab","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.120.090852_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.DMPK-11-RG-096","article-title":"Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake","volume":"27","author":"Shitara","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.120.090852_bib23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/mol.115.101832","article-title":"Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy","volume":"89","author":"Sykes","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.120.090852_bib24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1693","article-title":"Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated drug-drug interactions: current capabilities, case studies, future opportunities, and recommendations","volume":"107","author":"Taskar","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090852_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.090852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:49:29Z","timestamp":1740055769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0090955624079418"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.090852","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.090852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}